share_log

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd's (SHSE:600721) Largest Shareholders Are Individual Investors Who Were Rewarded as Market Cap Surged CN¥405m Last Week

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd's (SHSE:600721) Largest Shareholders Are Individual Investors Who Were Rewarded as Market Cap Surged CN¥405m Last Week

新疆白花村醫藥科技股份有限公司, Ltd(SHSE: 600721)的最大股東是個人投資者,上週市值飆升4.05億元人民幣,他們獲得了回報
Simply Wall St ·  03/15 06:54

Key Insights

關鍵見解

  • The considerable ownership by individual investors in Xinjiang Bai Hua Cun Pharma TechLtd indicates that they collectively have a greater say in management and business strategy
  • 41% of the business is held by the top 15 shareholders
  • Ownership research, combined with past performance data can help provide a good understanding of opportunities in a stock
  • 個人投資者在新疆白花村醫藥科技有限公司擁有大量所有權,這表明他們在管理和業務戰略中集體擁有更大的發言權
  • 41% 的業務由前 15 名股東持有
  • 所有權研究與過去的表現數據相結合,可以幫助人們更好地了解股票的機會

Every investor in Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd (SHSE:600721) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 59% to be precise, is individual investors. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

新疆白花村醫藥科技有限公司的每一位投資者, Ltd(上海證券交易所代碼:600721)應該知道最強大的股東群體。持有公司股份最多的集團是個人投資者,準確地說約爲59%。換句話說,該集團將從對公司的投資中獲得最多(或損失最大)。

As a result, individual investors were the biggest beneficiaries of last week's 19% gain.

因此,個人投資者是上週19%漲幅的最大受益者。

Let's take a closer look to see what the different types of shareholders can tell us about Xinjiang Bai Hua Cun Pharma TechLtd.

讓我們仔細看看不同類型的股東能告訴我們關於新疆白花村醫藥科技有限公司的哪些信息。

ownership-breakdown
SHSE:600721 Ownership Breakdown March 14th 2024
SHSE: 600721 所有權明細 2024 年 3 月 14 日

What Does The Institutional Ownership Tell Us About Xinjiang Bai Hua Cun Pharma TechLtd?

機構所有權告訴我們關於新疆百花村醫藥科技有限公司的哪些信息?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

機構在向自己的投資者報告時通常會根據基準來衡量自己,因此,一旦股票被納入主要指數,他們通常會對股票更加熱情。我們預計大多數公司都會有一些機構在冊,尤其是在它們正在成長的情況下。

Since institutions own only a small portion of Xinjiang Bai Hua Cun Pharma TechLtd, many may not have spent much time considering the stock. But it's clear that some have; and they liked it enough to buy in. So if the company itself can improve over time, we may well see more institutional buyers in the future. When multiple institutional investors want to buy shares, we often see a rising share price. The past revenue trajectory (shown below) can be an indication of future growth, but there are no guarantees.

由於機構僅擁有新疆白花村製藥科技有限公司的一小部分股份,因此許多機構可能沒有花太多時間考慮這隻股票。但很明顯,有些人有;他們很喜歡它,足以買進。因此,如果公司本身能夠隨着時間的推移而有所改善,那麼將來我們很可能會看到更多的機構買家。當多個機構投資者想要購買股票時,我們經常會看到股價上漲。過去的收入軌跡(如下所示)可以預示未來的增長,但無法保證。

earnings-and-revenue-growth
SHSE:600721 Earnings and Revenue Growth March 14th 2024
SHSE: 600721 2024 年 3 月 14 日收益和收入增長

We note that hedge funds don't have a meaningful investment in Xinjiang Bai Hua Cun Pharma TechLtd. Our data shows that Hualing Group Investment Holding (Xinjiang) Co., Ltd. is the largest shareholder with 21% of shares outstanding. In comparison, the second and third largest shareholders hold about 4.4% and 4.2% of the stock.

我們注意到,對沖基金在新疆白花村醫藥科技有限公司沒有進行有意義的投資。我們的數據顯示,華菱集團投資控股(新疆)有限公司是最大股東,已發行股份爲21%。相比之下,第二和第三大股東持有約4.4%和4.2%的股份。

A deeper look at our ownership data shows that the top 15 shareholders collectively hold less than half of the register, suggesting a large group of small holders where no single shareholder has a majority.

深入研究我們的所有權數據後發現,前15名股東共持有不到一半的股份,這表明在很大一部分小股東中,沒有一個單一股東佔多數。

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. As far as we can tell there isn't analyst coverage of the company, so it is probably flying under the radar.

研究機構所有權是衡量和篩選股票預期表現的好方法。通過研究分析師的情緒也可以達到同樣的目的。據我們所知,沒有分析師對該公司進行報道,因此它可能處於雷達之下。

Insider Ownership Of Xinjiang Bai Hua Cun Pharma TechLtd

新疆百花村醫藥科技有限公司的內部人所有權

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

儘管內部人士的確切定義可能是主觀的,但幾乎每個人都認爲董事會成員是內部人士。公司管理層對董事會負責,後者應代表股東的利益。值得注意的是,有時高層管理人員自己也是董事會成員。

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

我通常認爲內部所有權是一件好事。但是,在某些情況下,這使其他股東更難追究董事會對決策的責任。

We can see that insiders own shares in Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd. In their own names, insiders own CN¥229m worth of stock in the CN¥2.5b company. It is good to see some investment by insiders, but it might be worth checking if those insiders have been buying.

我們可以看到,內部人士擁有新疆白花村醫藥科技有限公司的股份。, Ltd. 內部人士以自己的名義擁有這家價值25億元人民幣的公司中價值2.29億元人民幣的股票。很高興看到內部人士進行一些投資,但可能值得檢查一下這些內部人士是否在買入。

General Public Ownership

一般公有制

The general public, who are usually individual investors, hold a substantial 59% stake in Xinjiang Bai Hua Cun Pharma TechLtd, suggesting it is a fairly popular stock. With this amount of ownership, retail investors can collectively play a role in decisions that affect shareholder returns, such as dividend policies and the appointment of directors. They can also exercise the power to vote on acquisitions or mergers that may not improve profitability.

公衆通常是個人投資者,他們持有新疆白花村製藥科技有限公司59%的大量股份,這表明它是一隻相當受歡迎的股票。有了這麼多的所有權,散戶投資者可以在影響股東回報的決策中共同發揮作用,例如股息政策和董事任命。他們還可以對可能不會提高盈利能力的收購或合併行使投票權。

Private Company Ownership

私人公司所有權

We can see that Private Companies own 30%, of the shares on issue. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

我們可以看到,私人公司擁有已發行股份的30%。私營公司可能是關聯方。有時,內部人士通過控股私營公司而對上市公司擁有權益,而不是以個人身份擁有權益。儘管很難得出任何寬泛的結論,但值得注意的是,這是一個需要進一步研究的領域。

Next Steps:

後續步驟:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too.

我覺得看看究竟是誰擁有一家公司非常有趣。但是,要真正獲得見解,我們也需要考慮其他信息。

I like to dive deeper into how a company has performed in the past. You can find historic revenue and earnings in this detailed graph.

我喜歡更深入地了解一家公司過去的表現。您可以在這張詳細圖表中找到歷史收入和收入。

If you would prefer check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, backed by strong financial data.

如果你更願意去另一家公司看看,一家財務狀況可能更好,那麼千萬不要錯過這份由強勁財務數據支持的有趣公司的免費名單。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的數字是使用過去十二個月的數據計算得出的,這些數據是指截至財務報表日期當月最後一天的12個月期間。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論